International Medical Case Reports Journal (Aug 2020)
New-Onset Uveitis Possibly Caused by Secukinumab in a 47-Year-Old Male Patient with Long-Standing Ankylosing Spondylitis
Abstract
Huda Nadwi,1 Murad Janaini,1 Mohammed Zammo,2 Mohamed Cheikh,2 Hani Almoallim1– 3 1Department of Medicine, College of Medicine, Umm Alqura University, Makkah, Saudi Arabia; 2Department of Medicine, Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia; 3Alzaidi Chair of Research in Rheumatic Diseases, Umm Alqura University, Makkah, Saudi ArabiaCorrespondence: Hani AlmoallimDepartment of Medicine, College of Medicine, Umm Alqura University, P.O. Box 1821, Jeddah 21441, Saudi ArabiaTel +966 505703935Email [email protected]: Secukinumab, “an IL-17 antagonist”, is one of the biological agents used to treat active ankylosing spondylitis (AS). Although it has been proven that certain agents are linked with a paradoxical increase in uveitis, there are limited data on whether secukinumab has this effect or not. We report a case of a new-onset anterior uveitis after 6 months of starting secukinumab in a 47-year-old male, HLA-B27 positive AS patient. He had a long-standing history with the disease over 25 years. He was treated in the past with methotrexate then adalimumab and later on with etanercept. He had no history of uveitis during all of this time. The uveitis was mild and treated conventionally with local measures while secukinumab was maintained. After a close follow-up, the uveitis had completely resolved. Is this part of the original disease or a possible side effect from secukinumab?Keywords: spondyloarthritis, iritis, IL-17A inhibitors, biologics, ankylosing spondylitis, uveitis, secukinumab
